Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2005-05-17
2005-05-17
Nguyen, Dave Trong (Department: 1635)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S135100, C424S139100, C424S141100, C530S351000
Reexamination Certificate
active
06893637
ABSTRACT:
Materials and Methods for treating fibrosis in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf3 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Zvegf3 antagonists include anti-zvegf3 antibodies, mitogenically inactive receptor-binding zvegf3 variant polypeptides, and inhibitory polynucleotides. Within one embodiment of the fibrosis is liver fibrosis.
REFERENCES:
patent: 5238950 (1993-08-01), Clader et al.
patent: 5700823 (1997-12-01), Hirth et al.
patent: 6455283 (2002-09-01), Ferrara et al.
patent: 9947677 (1999-09-01), None
patent: 0034474 (2000-06-01), None
patent: 0059940 (2000-10-01), None
M Clark, Immunology Today, “Antibody humanization: a case of the ‘Emperor's new clothes’?” Aug. vol. 21, No. 8, pp. 397-402.*
Yu L. et al. Therapeutic stratagies to halt renal fibrosis. Current Opin. Pharm. 2002; 2:177-181.
Kitamura Y. et al. A loss-of-function mutation of c-kit results in depletion of mast cells andinterstitial cells of Cajal, while its gain-of-function mutation results in their oncogenesis. Mutation Research 2001; 477:165-171.
Dhanasekaran N. et al. Regulation of cell proliferation by G proteins. Oncogene 1989; 17:1383-1394.
Mann D.A. et al. Transcreiptional regulationof hepatic stellate cell activation (Gut 2002; 50:891-896).
Martinet et al.,New England Journal of Medicine 317:202-209, 1987.
Deuel et al.,New England Journal of Medicine 317:236, 1987.
Isaka et al.,J. Clin. Invest. 92:2597-2601, 1993.
Yoshida et al.,Biochem. Biophys. Res. Comm. 265: 503-508, 1999.
Johnson et al.,J. Exp. Med. 175: 1413-1416, 1992.
Rice et al., Am. J. Path. 155: 213-221, 1999.
Yi et al.,Am. J. Path. 149:539-548, 1996.
Floege et al.,J. Clin. Invest. 92: 2952-2962, 1993.
Li et al.,Nature Cell Biol. 2: 302-309, 2000.
Bergsten et al.,Nature Cell Biol. 3: 512-516, 2001.
LaRochelle et al.,Nature Cell Biol. 3: 517-521, 2001.
Uutela et al.,Circulation 103: 2242-2247, 2001.
Johnson et al.,J. Exp. Med. 175: 1413-1416, 1992.
Preaux et al.,Hepatology 26: 315-322, 1997.
Kallio et al.,Am. J. Respir. Crit. Care Med. 160: 1324-1332, 1999.
Yagi et al.,Gen. Pharmac. 31: 765-773, 1998.
Pinzani et al.,Brit. J. Pharmac. 119: 1117-1124, 1996.
Friedman,Seminars in Liver Disease 19: 129-140, 1999.
Li et al.,Journal of Gastroenterology and Hepatology 14: 618-633, 1999.
Brady et al.,Biochem.Biophys. Res. Comm.248: 174-179, 1998.
Heldin et al.,Physiological Reviews 79: 1283-1316, 1999.
Isbrucker et al.,Tox. App. Pharmac. 149: 120-126, 1998.
Angell Jon Eric
Nguyen Dave Trong
Parker Gary E.
ZymoGenetics Inc.
LandOfFree
Method of treating fibrosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating fibrosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating fibrosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3434643